Oncolytics Biotech Inc.

ONC

CA6823108759

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 09:32:09 2024-07-05 EDT			5-day change	1st Jan Change
1.39 ^CAD	-2.11%		+2.96%	-22.35%

06-27	Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program	MT
06-27	Oncolytics Biotech Announces Productive FDA Type C Meeting on Its Metastatic Breast Cancer Program	CI

Andres Gutierrez to Resign as a Chief Medical Officer of Oncolytics Biotech Inc., Effective April 23, 2018

April 17, 2018 at 04:00 pm

Oncolytics Biotech Inc. announced that Andres Gutierrez, Chief Medical Officer at Oncolytics, will be leaving to pursue other opportunities, effective April 23, 2018.

Latest news about Oncolytics Biotech Inc.

Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program	06-27	MT
Oncolytics Biotech Announces Productive FDA Type C Meeting on Its Metastatic Breast Cancer Program	06-27	CI
Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on its Metastatic Breast Cancer Program	06-27	MT
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence	06-24	MT
Oncolytics Biotech President and CEO Coffey to Take Medical Leave of Absence	06-24	MT
Oncolytics Biotech Brief: Announcing President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence	06-24	MT
Oncolytics Biotech Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer	06-20	CI
Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX	06-20	MT
Oncolytics Biotech Brief: Says Dosed First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer	06-20	MT
Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting	05-24	CI
Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer	05-24	MT
Transcript : Oncolytics Biotech Inc. - Shareholder/Analyst Call	05-15
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial	05-15	MT
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	05-15	CI
Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	05-15	MT
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	05-15	CI
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA	05-13	MT
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million	05-09	MT
Transcript : Oncolytics Biotech Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Oncolytics Biotech Brief: Q1 Basic and diluted loss per common share $0.09	05-09	MT
Oncolytics Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer	05-09	MT
Oncolytics Biotech Brief: Says Received Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer	05-09	MT
Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer	05-09	CI
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	04-11	CI

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Companyâs primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.42 CAD

Average target price

6.625 CAD

Spread / Average Target

+366.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ONCOLYTICS BIOTECH INC.	-22.35%	79.61M
MODERNA, INC.	+16.99%	44.44B
LONZA GROUP AG	+42.04%	40.03B
IQVIA HOLDINGS INC.	-10.99%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.52%	31.46B
CELLTRION, INC.	-9.23%	27.29B
ICON PUBLIC LIMITED COMPANY	+12.27%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.96%	13.8B
MEDPACE HOLDINGS, INC.	+30.20%	12.46B
BIO-TECHNE CORPORATION	-8.09%	11.26B

Other Biotechnology & Medical Research

Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Biotechnology & Medical Research

Andres Gutierrez to Resign as a Chief Medical Officer of Oncolytics Biotech Inc., Effective April 23, 2018

Latest news about Oncolytics Biotech Inc.

Chart Oncolytics Biotech Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research